The HLA system and immunological defence against cancer: a review!
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Human lymphocyte antigen (HLA) refers to a group of antigens coded for by genes on a single segment of chromosome 6 (Francke & Pellegrino 1977) . At present four separate loci have been demonstrated within this region, each coding for a series of from 8 to 20 alternate alleles (Table 1 ) (see Bach & Van Rood 1976) . The antigens of the A, Band C loci are detected using immune sera and complement in a Iymphocytotoxicity test, whereas the D locus antigens are defined by the mixed lymphocyte culture technique. Family studies have shown that every individual inherits from both parents a segment ofchromosome, known as a haplotype, coding for one antigen at each locus. In most families, the genes on a particular haplotype are always inherited together. However, on rare occasions, during meiosis, recombination occurs (less than I in 100) and this has enabled the exact sequence for the four loci to be established.
The extraordinary thing about this complicated system is why it should ever have evolved. AI  A2  A3  A9-AW23  A9-AW24   All   AW19-A29  AWI9-AW30  AWI9-AW31  AWI9-AW32  AWI9-AW33  A28  AW34  AW36  AW43   C locus   CW!  CW2  CW3  CW4  CW5   B locus   B5  B7  B8  BI2  BI3  BI4  BWI5  BWI6-BW38  BWI6-BW39  BWI7  BI8  BW21  BW22  B27  BW35  BW40  BW41  BW42   D locus   DWI  DW2  DW3  DW4  DW5  OW6  OW7  OW8 • W antigens are those which have received only provisional WHO ratification 5/ All animal species that have been studied, including the frog, chicken, mouse, rat, guinea-pig, dog, pig, sheep, Rhesus monkey and chimpanzee, have a complex lymphocyte antigen system like the HLA system. There is some evidence for close biochemical similarity between lymphocyte antigens of species as far removed phylogenetically as mouse, rat and man. This comes from both chemical purification and sequencing studies and the demonstration of immunological cross reactivity between the lymphocyte antigens of different species. The techniques used to study this gene complex have been the same for all species and three classes of gene product have been demonstrated. The antigens defined by antibodies are known as serologically defined antigens and exemplified by the A, Band C locus antigens of the HLA complex. The antigens defined by the mixed lymphocyte culture reaction, the lymphocyte activating antigens or determinants (LAD) -e.g. the HLA-O locus antigens -also have been demonstrated in all the species studied. The third class of gene, the immune response (Ir) gene, has so far been demonstrated only in experimental animals (Katz & Benacerraf 1975) , though there is a possibility that there are Ir genes in man situated close to the HLA-O locus. These genes regulate immune response, usually at the level of determining whether antigen recognition occurs.
HLA and transplantation rejection
In all species where this type of lymphocyte antigen has been studied, it can be detected on all tissues of the body and plays a significant role in initiating graft rejection. Since 1969 (Singal et al. 1969) , it has been well recognized in man, when using standard immunosuppression, that identity for HLA between siblings leads to almost indefinite renal graft survival, almost as often as when grafting between genetically identical twins. Matching for the HLA-A and B loci between unrelated individuals does produce some improvement in graft survival (Oliver et al. 1972) , though only when they are matched for the HLA-A, Band 0 loci does survival approach that of HLA identical siblings (Festenstein et al. 1976) .
The long evolutionary history of the major histocompatibility system and the occurrence of HLA and disease associations, make it highly likely that the real biological importance of the HLA system is in determining resistance/susceptibility to infectious and malignant disease. To understand the relevance of the HLA associations with malignancy, it will be necessary first to review the more important HLA associations with nonmalignant disease. HLA-B27 and ankylosing spondylitis More than 90 %of patients with ankylosing spondylitis are B27 positive, though the frequency of this antigen in a normal population is about 10% (Table 2) (Ryder & Svejgaard 1976) . The frequency of B27 in patients with ankylosing spondylitis approaches that of a positive rheumatoid factor in classical rheumatoid arthritis. However, more than 90 %of normals with B27 would not be expected to have overt symptoms of the disease (Table 3) . It is possible that this disease is under-diagnosed as the symptomatology could be confused with other conditions, but in a survey of B27-positive blood donors, Calin & Fries (1976) found only 18% with symptoms and X-ray changes of ankylosing spondylitis. Even amongst relatives of patients with the disease, less than half the B27-positive individuals had overt disease.
Studies of patients with a reactive arthropathy after salmonella, shigella and yersinia enteritis provide a possible explanation as to why there is not an absolute association between B27 and disease. The frequency of B27 is the same in these patients as in ankylosing spondylitis suggesting that there might be immunological cross reactivity between B27 and an antigen in gram negative bacteria (Table 4 ) (see Aho et al. 1973) . Supportive evidence for this hypothesis has come from Ebringer et 01. (1976) who immunized rabbits with B27 positive lymphocytes and produced antibodies against a species of klebsiella, and vice versa. Subsequently, an increased incidence of klebsiella organisms in patients with active disease was found. Confirmation of these results will be very important as they open completely new approaches to the treatment of these patients. Association of HLA antigens with abnormalities of immune response and resistance to viral disease Long before there was any knowledge of HLA antigen and disease associations, there were indications from studies of HLA antigen frequencies in different racial populations that HLA may have been of importance in terms of evolutionary selection (Bodmer 1972) . It was observed that amongst unrelated individuals certain pairs of A and B-Iocus antigens occurred more frequently together on the same chromosome (or haplotype) than would have been expected given the frequency of either antigen in the population under study. An example of this phenomena, known as linkage disequilibrium, is the association of A I and B8. More than 50 %of European Caucasians who were positive for A I were also B8 positive, and more than 65 %of B8-positive individuals were also A I positive. When methods for detecting D-Iocus antigens became available, the majority of A I/B8-positive individuals were also found to be DW3 positive. In contrast, in Asian Indians A I-positive individuals were never B8 positive, but more commonly than expected B17, while in Africa, Zambian Negro B8-positive individuals were rarely A I positive, but more frequently than expected AW30. These studies suggest that. there may have been selective pressure in each particular area, which has encouraged survival of individuals with the genes within the specifically selected haplotype.
When HLA and disease studies first started, it was surprising to discover that the haplotype most frequently associated with disease in Caucasians was also the most frequent in normal populations. However, all the diseases associated with A 1/88, and DW3 when it was tested for, were chronic diseases which had negligible incidence at the time that infectious disease was a dominant cause of death in Europeans (see Table 5 ) (Ryder & Svejgaard 1976) . All of them were found to be associated with abnormalities of immune response and were in the main autoimmune diseases. Studies of immune response of A 1/88-positive individuals showed stronger responsiveness in mixed lymphocyte culture, higher antibody titres against bacterial antigens, higher frequency of autoantibodies and more likelihood of kidney graft rejection. than A I/B8-negative controls (see Oliver 1977) . The importance of this enhanced responsiveness in recovery from viral disease was demonstrated by Jungers et al. (1976) in a study of patients on chronic haemodialysis who developed hepatitis B antigenaemia. There was a significantly higher incidence of A 1/88 in patients who cleared the virus from the blood within three months than in those who became carriers of hepatitis 8 antigen.
HLA and malignant disease The demonstration (Lilly et al. 1964 ) that genes within the complex coding for the H2 antigens (murine equivalent of the HLA system) influenced survival of mice with Gross virus-induced leukaemia, provided the impetus for study of HLA antigens in human disease. Though malignant diseases, specifically Hodgkin's disease and acute leukaemia, were the first diseases studied. none of the associations reported in malignant disease have approached the level of significance found in the nonmalignant disease studies. Nevertheless, when the large numbers of series reported in the literature are analysed together, significant.associations such as that of Hodgkin's disease with 88 (Table 5 ) have emerged. This slight excess of 88 is consistently found in most of the series reported in the literature though in only a few was the difference significant (Ryder & Svejgaard 1976) . Similar weak associations of A2 with acute lymphoblastic leukaemia and A 10 with breast carcinoma have also been reported (Ryder & Svejgaard 1976) . Most of these reports did not take account of the clinical stage of the patient at the time that HLA typing was performed. An important insight into the nature of the HLA association with malignant disease came when Falk & Osoba (1971) reported that A 1/88 had a significantly higher incidence in patients with Hodgkin's disease tested more than 5 years after diagnosis than in those patients who had been treated for less than one year. It was postulated that this might be due to HLA associated resistance factors which influenced survival. There have been several reports since, associating certain HLA antigens with survival of patients with other types of malignant disease (Rogentine et al. 1973 , Lawler et al. 1974 , Dellon et al. 1975 . Acute myeloid leukaemia was the only disease other than Hodgkin's disease where resistance was associated with the A I/BS haplotype (Table 6 ). The A I/BS haplotype is the one which has been associated with enhanced immunoresponsiveness in the studies ofHLA antigens in nonmalignant disease, and it is possible that the same mechanism is responsible for its influence on survival in Hodgkin's disease and acute myeloid leukaemia. The possibility that there may be other genes within the HLA region which determine susceptibility to malignant disease has been suggested by Lynch et al. (1975) who found that in a family with a very high incidence of malignant disease the haplotype A2/B 12 showed a strong association with this occurrence. Our own findings in the families of patients with Hodgkin's disease and acute myeloid leukaemia, where a second malignancy has occurred, do not support this, suggesting that it is only relevant in families where the susceptibility gene is well expressed.
Summary
In nonmalignant disease, there have been two mechanisms implicated in the association of HLA antigens with disease. In ankylosing spondylitis, evidence is accumulating for cross tolerance between a bacterial antigen and the HLA-B27 antigen; while in the autoimmune diseases, the involvement of an abnormal 'immune response gene, associated with A J/B8 haplotype, is strongly suspected. The same haplotype has also been associated with recovery from hepatitis B infection and survival of patients with Hodgkin's disease and acute myeloid leukaemia. At present, there are no techniques to study directly immune response genes in man and so these observations are still strictly academic. However, with increasing interest in the use of immunotherapy in cancer and the demonstration in mice that the major histocompatibility system may be the site of action of soluble mediators of immune memory, understanding the mechanisms of action of the HLA associated resistance factors may enable a more rational approach to immunotherapy in man.
